Clinical trial · Observational
Predicting Effective Therapy in Pancreatic Cancer
Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response
NCT03033927CI-TRIAL-00109512active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CTC isolocation and analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with Stage IV Pancreatic Cancer
- interventionNames
- Diagnostic Test: CTC isolocation and analysis
Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- 36 months
- description
- in patients receiving frontline therapy predicted to be effective versus ineffective based on CTC PGx analysis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment. * Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents. * Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted. * ECOG performance status 0-2. * A minimum age of 18 years old. Exclusion Criteria: * Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma * Known to be HIV positive on antiretroviral therapy * Prior organ allograft * Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures
References
Publications (1)
- DERIVEDYu KH, Park J, Mittal A, Abou-Alfa GK, El Dika I, Epstein AS, Ilson DH, Kelsen DP, Ku GY, Li J, Park W, Varghese AM, Chou JF, Capanu M, Cooper B, Bartlett A, McCarthy D, Sangar V, McCarthy B, O'Reilly EM. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Cancer. 2022 Aug 1;128(15):2958-2966. doi: 10.1002/cncr.34269. Epub 2022 Jun 1. PMID 35647938